ClearPoint Neuro faces securities fraud investigation after drug trial data disappoints investors

Pomerantz LLP is investigating ClearPoint Neuro and its executives for potential securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that a Huntington's disease treatment failed to meet key clinical goals in Phase I/II trials. This news caused ClearPoint's shares to fall over 23% on September 29, 2026. Investors who suffered losses are encouraged to contact Pomerantz LLP as the investigation explores possible unlawful business practices by the company and its leadership.

ClearPoint Neuro's shares have rebounded somewhat since the reported clinical trial setback, trading at USD 9.50 with a 1-day gain of 3.60% on Pluang. The stock's market cap stands at $279.72 million, reflecting ongoing investor interest despite recent challenges. These figures are current as of Oct 21, 2026 03:12 WIB.